Results for: TOVX

Theriva Biologics Inc. (TOVX) stock is on the rise this week, driven by a series of positive developments, including the FDA’s granting of Rare Pediatric Drug Designation (RPDD) for its retinoblastoma treatment, VCN-01, and the allowance of a patent application for treating C. difficile disease. The company’s recent reverse stock split has also contributed to price volatility.

Theriva Biologics Inc. (TOVX) shares have plummeted 15% after the company announced a 1-for-25 reverse stock split, effective August 26. The move aims to ensure the company meets NYSE American listing requirements. This article explores the implications of the reverse split and provides insights into potential investment strategies.